![]() |
市場調査レポート
商品コード
959700
RT 100:新興医薬品の考察・市場予測 (2030年)RT 100 - Emerging Drug Insight and Market Forecast - 2030 |
RT 100:新興医薬品の考察・市場予測 (2030年) |
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 50 Pages
納期: 約10営業日
|
RT-100は、心臓カテーテル検査(血管造影と同様の一般的に行われる外来処置)中に、心臓に栄養を供給する動脈に直接注入される治験用遺伝子治療製品です。この遺伝子導入方法は、安全かつ効率的にAC6を心筋細胞に直接送達することが示されています。ヒトAC6をコード化する遺伝子は、細胞に入ることができますが、それ自体は再生できない改変されたアデノウイルスベクターを介して送達されます(Ad5.hAC6)。 AC6は心臓に取り込まれ、心筋細胞で持続することが示されています。身体への要求を減らすために働く小分子薬物治療とは異なり、この遺伝子治療は全体的な心臓機能の改善を目的としています。
当レポートでは、米国、欧州5ヶ国(ドイツ、フランス、イタリア、スペイン、英国)、および日本の7つの主要市場における RT-100 について詳細に説明し (作用機序、投与量、合成経路、規制のマイルストーンを含む研究開発活動、およびその他の開発活動)、SWOT分析、市場の競合企業、およびその他の新たな治療法を含む将来の市場評価を提供しています。
"RT 100 - Emerging Drug Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Heart failure in 7 Major Markets. A detailed picture of the RT 100 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2020-2030 is provided in this report along with a detailed description of the product. The product details cover mechanism of action, dosage and administration, route of synthesis, and Research and development activity including regulatory milestones, and other development activities. Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.
RT-100 is an investigational gene therapy product that is infused during cardiac catheterization - a commonly performed outpatient procedure similar to an angiography - directly into the arteries that feed the heart. This method of gene transfer has been shown to safely and efficiently deliver AC6 directly to heart muscle cells. The gene encoding human AC6 is delivered via a modified adenovirus vector that is able to enter the cells but cannot reproduce itself (Ad5.hAC6). The AC6 is taken in by the heart and has been shown to persist in heart muscle cells. Unlike small molecule drug treatments, which work to decrease demands on the body, this gene therapy is aimed at improving overall heart function. Rather than slow progression or minimize symptoms of CHF, RT-100 has the potential to halt and reverse the CHF-induced remodeling of the heart, enabling it to pump more effectively. Granted Fast Track designation by the U.S. Food and Drug Administration (FDA), RT-100 is in late-stage clinical development.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
RT 100 Analytical Perspective by DelveInsight
This report provides a detailed market assessment of RT 100 in Seven Major Markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2020 to 2030.
The report provides the clinical trials information of RT 100 covering trial interventions, trial conditions, trial status, start and completion dates.